Illumina has partnered with Vitrolife to sell our preimplantation genetic screening (PGS) and karyomapping products. Please contact Vitrolife for any sales and support.

VeriSeq PGS Kit

A next-generation sequencing solution that provides accurate chromosome screening for identification of in vitro embryos most likely to be euploid. Read More...
Select Product(s)

VeriSeq PGS Kit (96 samples)



MiSeq Reagent Kit v3 - PGS (24 samples)



Product Highlights

The VeriSeq PGS Kit takes advantage of next-generation sequencing (NGS) technology to provide comprehensive, accurate screening of all 24 chromosomes for identification of in vitro embryos most likely to be euploid. Preimplantation genetic screening (PGS) results generated using the VeriSeq PGS Kit are comparable to those achieved with the widely used array-based 24sure technology. In addition, NGS offers the opportunity for improved assay workflow, higher throughput, and enhanced performance.1

  • Fast, streamlined workflow: Sample to answer in approximately 12 hours
  • High-throughput analysis: Screen up to 24 samples per run
  • Ultra-Low Input: NGS offers a highly sensitive method for screening in vitro embryos, requiring as little as 1 ng of DNA from a SurePlex DNA amplification reaction. DNA can be obtained from a blastomere biopsy, from a day 3 embryo, or from a trophectodermal (TE) biopsy from a blastocyst.

Learn more about preimplantation genetic screening.

Frequently Purchased Together


Method-Specific Workflow Example


The 24sure Microarray has been discontinued. VeriSeq PGS provides an alternative solution for this application. Illumina remains committed to providing you with high-quality support and service.

Related Products

  1. Fiorentino F, Bono S, Biricik A, et al. Application of next-generation sequencing technology for comprehensive aneuploidy screening of blastocysts in clinical preimplantation genetic screening cycles. Hum Reprod. 2014;29(12):2802–2813.
  2. Yang Z, Liu J, Collins GS, Salem SA, et al. Selection of single blastocysts for fresh transfer via standard morphology assessment alone and with array CGH for good prognosis patients: results from a randomised pilot study. Mol Cytogenet. 2012;5: 24.